Form 4: SOPHIA GENETICS SA: Insider Sells Shares for Tax Withholding

SOPHIA GENETICS SA reports that Chief Scientific Officer Zhenyu Xu sold shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

Summary

• Zhenyu Xu, Chief Scientific Officer of SOPHiA GENETICS SA, sold a total of 4,720 ordinary shares on April 10 and April 13, 2026.
• These sales were conducted to satisfy tax withholding obligations arising from the vesting of restricted stock units on April 2 and 3, 2026.
• All transactions were executed under a pre-established Rule 10b5-1(c) trading plan, indicating they were not discretionary trades.
• The sales occurred at weighted average prices, with individual transaction prices ranging between $4.61 and $4.88.
• Following these transactions, Zhenyu Xu beneficially owns 632,096 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While insider selling can be a negative signal, the clear explanation of tax withholding and the use of a Rule 10b5-1(c) plan mitigate concerns about discretionary selling or lack of confidence.

Positives

• The sales were executed under a Rule 10b5-1(c) trading plan, which is designed to comply with insider trading regulations and provides an affirmative defense against allegations of insider trading.
• The transactions were specifically to cover tax withholding obligations, a common and expected event for executives receiving equity compensation.

Negatives

• Insider selling, even if for tax purposes, can sometimes be perceived negatively by the market.
• The weighted average sale price indicates a range of prices, suggesting a need for further detail on specific transaction prices if granular analysis is required.

Risks

• While the sales are compliant with Rule 10b5-1(c), any perception of significant insider selling could negatively impact investor sentiment.
• The company's stock price may be sensitive to the volume and timing of insider sales, especially if they are perceived as a signal of reduced confidence by management.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it pertains to past transactions.

Management Comments

• Sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
• The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1(c) plan by SOPHiA GENETICS SA's Chief Scientific Officer is a common practice for executives to manage equity holdings and comply with regulatory requirements, particularly when dealing with tax obligations from equity awards.

Stakeholder Impact

• Shareholders: May perceive insider selling as a negative signal, although the explanation of tax withholding and the Rule 10b5-1(c) plan should temper this concern.
• Employees: The transaction is related to executive compensation and tax obligations, with no direct impact on other employees.
• Management: The transaction demonstrates adherence to regulatory requirements for managing equity compensation and tax liabilities.

Next Steps

• The reporting person will continue to hold shares beneficially owned after these transactions.
• The company may receive written requests for detailed pricing information regarding the sales.

Key Dates

Keywords

SOPHIA GENETICS SA, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Tax Withholding, Restricted Stock Units, Executive Compensation, Beneficial Ownership, Zhenyu Xu